Published in J Immunol on May 17, 2013
Resolvin D1 activates the inflammation resolving response at splenic and ventricular site following myocardial infarction leading to improved ventricular function. J Mol Cell Cardiol (2015) 1.54
The role of the FPR2/ALX receptor in atherosclerosis development and plaque stability. Cardiovasc Res (2014) 1.51
Ligand-specific conformational change of the G-protein-coupled receptor ALX/FPR2 determines proresolving functional responses. Proc Natl Acad Sci U S A (2013) 1.49
Update on leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR Review 7. Br J Pharmacol (2014) 1.03
Wound repair: role of immune-epithelial interactions. Mucosal Immunol (2015) 1.00
Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies. Nat Rev Drug Discov (2016) 0.92
Nonredundant protective properties of FPR2/ALX in polymicrobial murine sepsis. Proc Natl Acad Sci U S A (2014) 0.91
Annexin A1 and the Resolution of Inflammation: Modulation of Neutrophil Recruitment, Apoptosis, and Clearance. J Immunol Res (2016) 0.83
Biasing the lipoxin A4/formyl peptide receptor 2 pushes inflammatory resolution. Proc Natl Acad Sci U S A (2013) 0.83
Endogenous annexin A1 is a novel protective determinant in nonalcoholic steatohepatitis in mice. Hepatology (2014) 0.83
Pharmacological Treatment with Annexin A1 Reduces Atherosclerotic Plaque Burden in LDLR-/- Mice on Western Type Diet. PLoS One (2015) 0.81
Identification of C-terminal phosphorylation sites of N-formyl peptide receptor-1 (FPR1) in human blood neutrophils. J Biol Chem (2013) 0.81
Switching off key signaling survival molecules to switch on the resolution of inflammation. Mediators Inflamm (2014) 0.80
Discovery of specialized pro-resolving mediators marks the dawn of resolution physiology and pharmacology. Mol Aspects Med (2017) 0.77
Biomarker-guided clinical development of the first-in-class anti-inflammatory FPR2/ALX agonist ACT-389949. Br J Clin Pharmacol (2016) 0.75
Characterizing the anti-inflammatory and tissue protective actions of a novel Annexin A1 peptide. PLoS One (2017) 0.75
The advantageous role of annexin A1 in cardiovascular disease. Cell Adh Migr (2016) 0.75
Rab17 mediates differential antigen sorting following efferocytosis and phagocytosis. Cell Death Dis (2016) 0.75
Interaction between ANXA1 and GATA-3 in Immunosuppression of CD4(+) T Cells. Mediators Inflamm (2016) 0.75
Resolution of inflammation: state of the art, definitions and terms. FASEB J (2007) 5.12
Inflammatory resolution: new opportunities for drug discovery. Nat Rev Drug Discov (2004) 5.08
Role of the immune system in chronic pain. Nat Rev Neurosci (2005) 4.10
Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature (2009) 3.27
Aberrant inflammation and resistance to glucocorticoids in annexin 1-/- mouse. FASEB J (2002) 2.13
Resolution of inflammation: an integrated view. EMBO Mol Med (2013) 2.01
Morning blood pressure surge as a destabilizing factor of atherosclerotic plaque: role of ubiquitin-proteasome activity. Hypertension (2007) 1.77
Modulation of phagocytosis of apoptotic neutrophils by supernatant from dexamethasone-treated macrophages and annexin-derived peptide Ac(2-26). J Immunol (2005) 1.68
Resolvin D1 limits polymorphonuclear leukocyte recruitment to inflammatory loci: receptor-dependent actions. Arterioscler Thromb Vasc Biol (2012) 1.67
Tight glycemic control reduces heart inflammation and remodeling during acute myocardial infarction in hyperglycemic patients. J Am Coll Cardiol (2009) 1.67
Annexin 1 and its bioactive peptide inhibit neutrophil-endothelium interactions under flow: indication of distinct receptor involvement. Blood (2005) 1.62
Annexin 1 mediates the rapid anti-inflammatory effects of neutrophil-derived microparticles. Blood (2008) 1.61
Leukocyte antiadhesive actions of annexin 1: ALXR- and FPR-related anti-inflammatory mechanisms. Blood (2003) 1.60
Annexin A1, formyl peptide receptor, and NOX1 orchestrate epithelial repair. J Clin Invest (2012) 1.57
Annexin I regulates SKCO-15 cell invasion by signaling through formyl peptide receptors. J Biol Chem (2006) 1.55
Cutting edge: Humanized nano-proresolving medicines mimic inflammation-resolution and enhance wound healing. J Immunol (2011) 1.52
Spatial and temporal profiles for anti-inflammatory gene expression in leukocytes during a resolving model of peritonitis. J Immunol (2006) 1.52
Ligand-specific conformational change of the G-protein-coupled receptor ALX/FPR2 determines proresolving functional responses. Proc Natl Acad Sci U S A (2013) 1.49
Acute hyperglycemia induces nitrotyrosine formation and apoptosis in perfused heart from rat. Diabetes (2002) 1.48
Annexin 1-deficient neutrophils exhibit enhanced transmigration in vivo and increased responsiveness in vitro. J Leukoc Biol (2005) 1.43
The link module from human TSG-6 inhibits neutrophil migration in a hyaluronan- and inter-alpha -inhibitor-independent manner. J Biol Chem (2002) 1.39
Modulation of inflammation and response to dexamethasone by Annexin 1 in antigen-induced arthritis. Arthritis Rheum (2004) 1.39
Myocardial lipid accumulation in patients with pressure-overloaded heart and metabolic syndrome. J Lipid Res (2009) 1.38
Hyperglycemia in streptozotocin-induced diabetic rat increases infarct size associated with low levels of myocardial HO-1 during ischemia/reperfusion. Diabetes (2005) 1.37
NCX-1015, a nitric-oxide derivative of prednisolone, enhances regulatory T cells in the lamina propria and protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis in mice. Proc Natl Acad Sci U S A (2002) 1.36
A novel calcium-dependent proapoptotic effect of annexin 1 on human neutrophils. FASEB J (2003) 1.30
Glucocorticoids induce protein S-dependent phagocytosis of apoptotic neutrophils by human macrophages. J Immunol (2009) 1.30
Therapeutic anti-inflammatory potential of formyl-peptide receptor agonists. Pharmacol Ther (2010) 1.29
Critical protective role for annexin 1 gene expression in the endotoxemic murine microcirculation. Am J Pathol (2005) 1.27
Antiinflammatory activity of soluble guanylate cyclase: cGMP-dependent down-regulation of P-selectin expression and leukocyte recruitment. Proc Natl Acad Sci U S A (2004) 1.26
Human beta-defensin 3 has immunosuppressive activity in vitro and in vivo. Eur J Immunol (2010) 1.26
FPR2/ALX receptor expression and internalization are critical for lipoxin A4 and annexin-derived peptide-stimulated phagocytosis. FASEB J (2010) 1.23
Activation of the annexin 1 counter-regulatory circuit affords protection in the mouse brain microcirculation. FASEB J (2007) 1.22
Advances in the pathophysiology of constitutive and inducible cyclooxygenases: two enzymes in the spotlight. Biochem Pharmacol (2003) 1.21
A novel biological activity for galectin-1: inhibition of leukocyte-endothelial cell interactions in experimental inflammation. Am J Pathol (2003) 1.20
Annexin A1 regulates intestinal mucosal injury, inflammation, and repair. J Immunol (2008) 1.18
Cannabinoid CB2 receptor activation reduces mouse myocardial ischemia-reperfusion injury: involvement of cytokine/chemokines and PMN. J Leukoc Biol (2003) 1.17
Oxidative stress as the leading cause of acute myocardial infarction in diabetics. Cardiovasc Drug Rev (2006) 1.17
Melanocortin receptor signaling in RAW264.7 macrophage cell line. Peptides (2005) 1.16
The ubiquitin-proteasome system and inflammatory activity in diabetic atherosclerotic plaques: effects of rosiglitazone treatment. Diabetes (2006) 1.16
Activation of melanocortin type 3 receptor as a molecular mechanism for adrenocorticotropic hormone efficacy in gouty arthritis. Arthritis Rheum (2002) 1.15
Expression of angiogenic factors during acute coronary syndromes in human type 2 diabetes. Diabetes (2004) 1.15
Novel insights into the inhibitory effects of Galectin-1 on neutrophil recruitment under flow. J Leukoc Biol (2008) 1.14
Annexin A1-containing extracellular vesicles and polymeric nanoparticles promote epithelial wound repair. J Clin Invest (2015) 1.13
Inhibitory control of endothelial galectin-1 on in vitro and in vivo lymphocyte trafficking. FASEB J (2007) 1.12
Ligand-specific glucocorticoid receptor activation in human platelets. Blood (2005) 1.12
Ligation of the adhesion-GPCR EMR2 regulates human neutrophil function. FASEB J (2007) 1.11
The ubiquitin-proteasome system contributes to the inflammatory injury in ischemic diabetic myocardium: the role of glycemic control. Cardiovasc Pathol (2009) 1.11
Annexin-1 modulates T-cell activation and differentiation. Blood (2006) 1.10
Annexin 1 cleavage in activated neutrophils: a pivotal role for proteinase 3. J Biol Chem (2007) 1.10
Circulating microRNA changes in heart failure patients treated with cardiac resynchronization therapy: responders vs. non-responders. Eur J Heart Fail (2013) 1.10
Increased activity of the ubiquitin-proteasome system in patients with symptomatic carotid disease is associated with enhanced inflammation and may destabilize the atherosclerotic plaque: effects of rosiglitazone treatment. J Am Coll Cardiol (2006) 1.09
Melanocortin 3 receptors control crystal-induced inflammation. FASEB J (2006) 1.08
An overview of the effects of annexin 1 on cells involved in the inflammatory process. Mem Inst Oswaldo Cruz (2005) 1.08
The peritoneal tumour microenvironment of high-grade serous ovarian cancer. J Pathol (2012) 1.07
Absence of inducible nitric oxide synthase reduces myocardial damage during ischemia reperfusion in streptozotocin-induced hyperglycemic mice. Diabetes (2004) 1.06
Interleukin 17 sustains rather than induces inflammation. Biochem Pharmacol (2008) 1.06
Anti-inflammatory and antiosteoclastogenesis properties of endogenous melanocortin receptor type 3 in experimental arthritis. FASEB J (2010) 1.06
Microparticle alpha-2-macroglobulin enhances pro-resolving responses and promotes survival in sepsis. EMBO Mol Med (2013) 1.05
Formyl-peptide receptor is not involved in the protection afforded by annexin 1 in murine acute myocardial infarct. FASEB J (2004) 1.05
Inhibitory effects of TSG-6 Link module on leukocyte-endothelial cell interactions in vitro and in vivo. Microcirculation (2004) 1.05
Aspirin and steroids: new mechanistic findings and avenues for drug discovery. Curr Opin Pharmacol (2005) 1.04
Increased adiposity, dysregulated glucose metabolism and systemic inflammation in Galectin-3 KO mice. PLoS One (2013) 1.04
The melanocortin agonist AP214 exerts anti-inflammatory and proresolving properties. Am J Pathol (2011) 1.03
Endogenous galectins and the control of the host inflammatory response. J Endocrinol (2009) 1.03
Annexin-1 modulates repair of gastric mucosal injury. Am J Physiol Gastrointest Liver Physiol (2008) 1.03
Interaction of human neutrophils with endothelial cells regulates the expression of endogenous proteins annexin 1, galectin-1 and galectin-3. Cell Biol Int (2006) 1.02
Heterogeneity in neutrophil microparticles reveals distinct proteome and functional properties. Mol Cell Proteomics (2013) 1.02
Regulation of leukocyte-endothelial interactions by glucocorticoids. Ann N Y Acad Sci (2002) 1.02
Spinal cathepsin S and fractalkine contribute to chronic pain in the collagen-induced arthritis model. Arthritis Rheum (2011) 1.01
Evidence for an anti-inflammatory loop centered on polymorphonuclear leukocyte formyl peptide receptor 2/lipoxin A4 receptor and operative in the inflamed microvasculature. J Immunol (2011) 1.00
Down-regulation of the anti-inflammatory protein annexin A1 in cystic fibrosis knock-out mice and patients. Mol Cell Proteomics (2005) 1.00
Impaired T cell activation and increased Th2 lineage commitment in Annexin-1-deficient T cells. Eur J Immunol (2007) 0.99
Activation of PPARbeta/delta inhibits leukocyte recruitment, cell adhesion molecule expression, and chemokine release. J Leukoc Biol (2009) 0.99
Functional and ultrastructural analysis of annexin A1 and its receptor in extravasating neutrophils during acute inflammation. Am J Pathol (2008) 0.99
Carbon monoxide-releasing molecules modulate leukocyte-endothelial interactions under flow. J Pharmacol Exp Ther (2007) 0.98
Characterisation of cystathionine gamma-lyase/hydrogen sulphide pathway in ischaemia/reperfusion injury of the mouse kidney: an in vivo study. Eur J Pharmacol (2009) 0.98
Up-regulation of Annexin-A1 and lipoxin A(4) in individuals with ulcerative colitis may promote mucosal homeostasis. PLoS One (2012) 0.98
Inflamed phenotype of the mesenteric microcirculation of melanocortin type 3 receptor-null mice after ischemia-reperfusion. FASEB J (2008) 0.98
A vasculo-protective circuit centered on lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 operative in murine microcirculation. Blood (2013) 0.98
A role for MC3R in modulating lung inflammation. Pulm Pharmacol Ther (2008) 0.97
Potent antiarthritic properties of a glucocorticoid derivative, NCX-1015, in an experimental model of arthritis. Proc Natl Acad Sci U S A (2002) 0.97
Design and characterization of a cleavage-resistant Annexin A1 mutant to control inflammation in the microvasculature. Blood (2010) 0.97
Chemokines as novel therapeutic targets in inflammatory diseases. Biochem Pharmacol (2002) 0.96
The impact of endogenous annexin A1 on glucocorticoid control of inflammatory arthritis. Ann Rheum Dis (2012) 0.96
Impaired phagocytic mechanism in annexin 1 null macrophages. Br J Pharmacol (2006) 0.96
Multiple functional targets of the immunoregulatory activity of galectin-1: Control of immune cell trafficking, dendritic cell physiology, and T-cell fate. Methods Enzymol (2010) 0.96